logo

For the Inventor, By the Inventor

Germantown, MD, United States of America

Rutul R Shah

This inventor holds 16 USPTO granted patents and 8 published patent applications. Top assignees: Precigen, Inc., Biopharma Credit Plc, as Collateral Agent. Active years: 2021-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Rutul R Shah. Retrieved from https://idiyas.com/inventor/rutul-r-shah

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16 

% Patents Active = 93.8

Average Co-Inventor Count = 2.7

ph-index = 2

Forward Citations = 11(Granted Patents)


Location History:

  • Boyds, MD (US) (2021 - 2023)
  • Germantown, MD (US) (2022 - 2024)
  • Blacksburg, VA (US) (2022 - 2024)

Company Filing History:

goldMedal14 out of 31 
 
Precigen, Inc.
 patents
silverMedal2 out of 5 
 
Biopharma Credit Plc, as Collateral Agent
 patents

Years Active: 2021-2026

Loading Chart...
16 patents (USPTO):Explore Patents
1. 12760083 - CHIMERIC RECEPTOR THERAPY (2026-10-13),
2. 12703747 - FUSION CONSTRUCTS AND METHODS OF USING THEREOF (2026-08-11),
3. 12559536 - CD33 SPECIFIC CHIMERIC ANTIGEN RECEPTORS (2026-02-24),
4. 12275772 - ROR-1 specific chimeric antigen receptors and uses thereof (2025-04-14),
5. 12194094 - Fusion constructs and methods of using thereof (2025-01-14),
6. 12180517 - Expression of novel cell tags (2024-12-31),
7. 12060585 - Expression of novel cell tags (2024-08-13),
8. 11981746 - MUC16 specific chimeric antigen receptors and uses thereof (2024-05-14),
9. 11976134 - MUC16 specific chimeric antigen receptors and uses thereof (2024-05-07),
10. 11946054 - Modulating expression of polypeptides via new gene switch expression systems (2024-04-02),
11. 11787848 - CD33 specific chimeric antigen receptors (2023-10-17),
12. 11771718 - Polypeptide compositions comprising spacers (2023-10-03),
13. 11692194 - Modulating expression of polypeptides via new gene switch expression systems (2023-07-04),
14. 11535669 - Fusion constructs and methods of using thereof (2022-12-27),
15. 11319380 - MUC16 specific chimeric antigen receptors and uses thereof (2022-05-03),

Title: Inventor Spotlight: Rutul R. Shah

Introduction

Rutul R. Shah, based in Germantown, MD, is a prominent inventor with a remarkable track record of 13 patents. His contributions to the field of cancer therapy through innovative chimeric antigen receptors (CARs) have positioned him as a leader in advancing medical technologies.

Latest Patents

Among his recent innovations, Shah developed a patent for "ROR-1 specific chimeric antigen receptors and uses thereof." This patent details CARs designed specifically for cancer therapy, incorporating a single-chain variable fragment (scFv) from an anti-ROR-1 monoclonal antibody. The patent highlights immune effector cells containing these CARs, emphasizing methods for treating proliferative disorders. Another significant patent involves "Fusion constructs and methods of using thereof," which describes a fusion protein consisting of an antibody component and a second component, which may include a cytokine trap or an adenosine deaminase. This innovative approach includes applications in cancer treatment, showcasing the potential of combining various biological components for therapeutic benefit.

Career Highlights

Rutul Shah is presently employed at Precigen, Inc., where his expertise in biotechnology and immunotherapy drives significant advancements. His focus on integrating novel components in cancer therapy continues to generate impactful innovations that address complex medical challenges.

Collaborations

Shah collaborates with esteemed colleagues such as Helen Sabzevari and Peter Emtage. Together, they push boundaries in research and development, significantly contributing to the company's mission of pioneering transformative therapies.

Conclusion

Rutul R. Shah's continuous innovation in the field of biomedical science, particularly around cancer therapy, highlights his dedication to improving patient outcomes through advanced technology. With 13 patents to his name and ongoing contributions at Precigen, Inc., he is undoubtedly a significant figure in the landscape of modern medical inventions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…